The prostate health index (PHI) test from Beckman Coulter Diagnostics, Brea, Calif, is a simple, multianalyte blood test that helps physicians distinguish prostate cancer from benign prostatic conditions in men aged 50 years or older. The test provides total prostate-specific antigen (PSA) results in the 4–10 ng/mL range, helping clinicians make more-informed biopsy decisions. The FDA-approved test may help to reduce the number of biopsies that are negative for prostate cancer. The test utilizes three different PSA markers (PSA, freePSA, and p2PSA) as part of a sophisticated algorithm designed to determine the probability of cancer in patients with elevated PSA levels more reliably. For more information, visit Beckman Coulter Diagnostics.
